-
公开(公告)号：US20230075092A1
公开(公告)日：2023-03-09
申请号：US17792403
申请日：2021-01-12
申请人： UNIVERSITE CLAUDE BERNARD LYON 1 , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , UNIVERSITE LAVAL , SIGNIA THERAPEUTICS , ECOLE NORMALE SUPERIEURE DE LYON
IPC分类号： A61K31/554 , A61K9/00 , A61K31/5383 , A61K45/06 , A61P31/16
摘要： The invention relates to a combination of Diltiazem and at least one viral polymerase inhibitor compound selected from among Baloxavir marboxil, Pimodivir, RO-7 and CC-42344. The invention relates in particular to the therapeutic use of said combination in the prevention and/or treatment of a viral infection, in particular of the respiratory and/or intestinal tract of a human or animal body.
-
公开(公告)号：US11504424B2
公开(公告)日：2022-11-22
申请号：US17262263
申请日：2019-07-12
申请人： UNIVERSITE CLAUDE BERNARD LYON 1 , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , ECOLE NORMALE SUPERIEURE DE LYON , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , UNIVERSITE LAVAL
发明人： Manuel Rosa-Calatrava , Guy Boivin , Julia Dubois , Mario Andres Pizzorno , Olivier Terrier , Marie-Eve Hamelin , Marie-Helene Cavanagh
IPC分类号： A61K39/155 , A61P31/14 , C12N7/00 , A61K39/00
摘要： The present invention relates to an attenuated virus strain derived from a human metapneumovirus strain comprising the genome sequence represented by sequence SEQ ID NO. 1, said attenuated strain comprising one or more genetic modifications of said sequence SEQ ID NO. 1 attenuating the virulence of said strain.
-
公开(公告)号：US20220178949A1
公开(公告)日：2022-06-09
申请号：US17052476
申请日：2019-05-02
申请人： HOSPICES CIVILS DE LYON , UNIVERSITE CLAUDE BERNARD LYON 1 , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
发明人： Le Duy DO , Jérôme HONNORAT , Véronique ROGEMOND
IPC分类号： G01N33/68 , G01N33/574 , G01N33/50
摘要： The invention relates to a process in vitro for diagnosing a paraneoplastic neurological syndrome (PNS) associated with a tumor in an individual, comprising the detection of at least one antibody chosen among antibodies against TRIM9 and antibodies against TRIM67, in a biological fluid of said individual.
-
公开(公告)号：US20220146402A1
公开(公告)日：2022-05-12
申请号：US17416268
申请日：2019-12-23
申请人： COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , CPE LYON , ECOLE CENTRALE DE LYON , INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON , UNIVERSITE CLAUDE BERNARD LYON 1
摘要： A particle detector includes at least one resonant cavity partially formed at least by a first reflector, a second reflector disposed at a distance from the first reflector and a channel located between the first and second reflectors, the channel being intended to receive at least one fluid comprising particles and to receive at least one light radiation; and at least one detection system having at least one photodetector. The particle detector is configured so that a portion of the light radiation present in the channel escapes from the cavity throughout the second reflector and reaches the detection system, thereby enabling the at least one photodetector to detect leakage of the cavity. The second reflector is a photonic crystal membranes PCM based reflector.
-
公开(公告)号：US11286557B2
公开(公告)日：2022-03-29
申请号：US16273510
申请日：2019-02-12
申请人： Commissariat A L'Energie Atomique Et Aux Energies Alternatives , Centre National De La Recherche Scientifique , Universite Claude Bernard Lyon 1 , CPE Lyon Formation Continue et Recherche
IPC分类号： C23C16/30 , C23C16/455 , C23C16/56 , C23C16/46 , C23C16/44
摘要： A method of preparing a crystalline thin film having a formula MY2 includes (1) preparing an MYx amorphous film by atomic layer deposition on a surface of a substrate, and (2) annealing the amorphous MYx film at 350° C. or more to provide the crystalline MY2 film. The amorphous MYx film is formed from at least one metal M precursor and at least one element Y precursor, wherein x is 1.5 to 3.1, M is tungsten or molybdenum, and Y is sulfur or selenium. Step (1) includes a) introducing a first metal M precursor or element Y precursor into a deposition chamber, b) purging with inert gas, c) introducing a second metal M precursor when the first precursor is element Y, or element Y precursor when the first precursor is metal M, d) purging with inert gas, e) repeating steps a) to d), and f) obtaining the amorphous MYx film.
-
公开(公告)号：US11229597B2
公开(公告)日：2022-01-25
申请号：US16498323
申请日：2018-04-03
发明人： Marion Dubald , Sandrine Bourgeois , Hatem Fessi , Martine Claret
摘要： The present invention relates to a novel pharmaceutical composition comprising doxycycline for topical application, in particular to the eye and eyelids. The invention also relates to this topical composition for use in the treatment of bacterial infections of the skin and mucous membranes.
-
公开(公告)号：US20210317265A1
公开(公告)日：2021-10-14
申请号：US17269637
申请日：2019-08-20
申请人： ROQUETTE FRERES , UNIVERSITE CLAUDE BERNARD LYON 1 , CENTRE NATIONAL DE LA RECHERECHE SCIENTIFIQUE -CNRS-
发明人： Nicolas JACQUEL , Sarah DEGRAS , Régis MERCIER , Thierry DELAUNAY
摘要： The present invention relates to a polymer of the aromatic polyether type, containing a biosourced furan diol, to a method for producing said polymer, and to the use of said polymer for producing membranes.
-
公开(公告)号：US11079391B2
公开(公告)日：2021-08-03
申请号：US15316525
申请日：2015-06-05
发明人： Pierre Miossec , Ndieme Thiam
IPC分类号： G01N33/68 , G01N33/50 , G01N33/53 , G01N33/563
摘要： The invention relates to an in vitro process for determining the functional IL-17 pro-inflammatory dependent level (IPDL) of a biological sample, comprising the following steps: a) measuring the level of an inflammatory marker produced by IL-17-sensitive cells incubated in the presence of a biological sample, b) measuring the level of said inflammatory marker produced by said cells incubated in the presence of a biological sample, in the presence of antibodies which neutralize the biological activity of IL-17, and c) determining the IPDL level, which is the difference between the level of said inflammatory marker measured in step a) and the level of said inflammatory marker measured in step b).
-
公开(公告)号：US20210178096A1
公开(公告)日：2021-06-17
申请号：US16074337
申请日：2017-02-02
申请人： INSTITUT NATIONAL DE LA SANTE ET DE RECHERCHE MEDICALE (INSERM) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , UNIVERSITE CLAUDE BERNARD LYON 1 , UNIVERSITE JEAN MONNET SAINT ETIENNE
发明人： Marc THEVENET , Patricia VIRET
摘要： The invention relates to a device for olfactory stimulation of a patient with a plurality of scents, said device comprising: —a source (2) of a carrier gas (G); —a plurality of scent odorization circuits, each odorization circuit (4) comprising: —a container (18) containing an odorous volatile substance (V), —a container inlet line (26), provided with a container inlet valve (28), connecting an inlet (30) of said container with said source of carrier gas, and —a container outlet line (36), provided with a container outlet valve (38), connecting an outlet (40) of said container with an exit line (12); —a control unit (8), configured to control said container inlet valve and container outlet valve according to a medical protocol.
-
公开(公告)号：US11006620B2
公开(公告)日：2021-05-18
申请号：US16062417
申请日：2016-12-15
IPC分类号： A01K67/00 , A01K67/027 , C12N5/073 , A61K49/00 , C12N5/09
摘要： The invention concerns a gallinacean embryo in which cancer cells have been grafted within the embryo tissue, characterised in that the embryo is at a developmental stage between the HH10 and HH25 stages at the time of the grafting, wherein said cancer cells are not neuroblastoma cells and said cells form tumors inside the embryo.
-
-
-
-
-
-
-
-
-
搜索结果
240 条记录 (耗时 0.04 秒)
